13 October 2011
EMA/816761/2011
Press Office

Public Statement

Alisade (fluticasone fuorate)

Cessation of validity of the marketing authorisation in the European Union

On 6 October 2008, the European Commission granted a marketing authorisation valid throughout the European Union (EU) for the medicinal product Alisade (fluticasone furoate), indicated for use in the treatment of the symptoms of allergic rhinitis. The marketing authorisation holder was notified on the 8 October 2008.

Alisade (fluticasone furoate) had not been marketed in Europe since this initial marketing authorisation. In accordance with article 14(4) of Regulation (EC) No 726/2004 ('sunset clause'), the marketing authorisation of a medicinal product lapses if the product has never been marketed in one of the Member States within three years of its initial authorisation.

Because of this, from 9 October 2011, the marketing authorisation for Alisade is no longer valid.

Avamys (fluticasone furoate) is an identical product authorised in the EU to treat the symptoms of allergic rhinitis.

Pursuant to the expiry of the marketing authorisation, the European Assessment Report (EPAR) for Alisade will be updated to reflect that the marketing authorisation is no longer valid.

Xavier Luria
Head of Sector of Safety and Efficacy
Human Medicines Development and Evaluation

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8427 **Facsimile** +44 (0)20 7418 8409
E-mail press@ema.europa.eu **Website** www.ema.europa.eu